Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
GSDMD-NT
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "GSDMD-NT" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-P83706
Synonyms: DF 5L; DF5L; DFNA 5L; DFNA5L; FKSG 10; FKSG10; FLJ12150; Gasdermin D; Gasdermin domain coNTaining 1; Gasdermin domain coNTaining protein 1; Gasdermin domain-coNTaining protein 1; Gasdermin-D; GasderminD; GSDMD_HUMAN; GSDMDC 1; GSDMDC1; Gasdermin-D, N-terminal; GSDMD-NT; hGSDMD-NTD; Gasdermin-D, C-terminal; GSDMD-CT; hGSDMD-CTD.
Cat. No.: HY-18711A
CAS No.: 1174161-86-4
Synonyms: Metatinib anhydrous; c-Met inhibitor 2
Target:
Research Areas:
SCR-1481B1 (Metatinib anhydrous; c-Met inhibitor 2) is an inhibitor of the N-terminal fragment of Gasdermin D (GSDMD), with an IC50 of 1.04 μM and a Ka of 0.42 μM in mice. SCR-1481B1 effectively blocks GSDMD-NT oligomerization and pore formation, inhibits GSDMD-mediated pyroptosis (Pyroptosis), preserves mitochondrial integrity, and reduces proinflammatory cytokine secretion. SCR-1481B1 also inhibits angiogenesis, exerts GSDMD-independent antitumor effects, and enhances the infiltration of antitumor immune cells. SCR-1481B1 is also an inhibitor targeting to c-MET and VEGFR2, can be used in studies related to melanoma and sepsis .
Cat. No.: HY-173234
CAS No.: 1008710-58-4
Target:
Research Areas:
GI-Y2 is an orally active, selective Gasdermin D (GSDMD) inhibitor (Kd = 36.0 μM) with anti-pyroptosis activity. GI-Y2 targets GSDMD, impairs membrane anchoring of GSDMD-NT, and blocks GSDMD‑dependent lipid binding and pore formation. GI-Y2 suppresses GSDMD‑dependent pyroptosis and inflammation, mitigates atherosclerosis and cardiac injury, boosts cell survival, and reduces IL‑1β/IL‑18 secretion. GI-Y2 can be used for the research of atherosclerosis and septic myocardial injury .
Cat. No.: HY-18711
CAS No.: 1174161-69-3
Synonyms: Metatinib free base; c-Met inhibitor 2 free base
Target:
Research Areas:
SCR-1481B1 (Metatinib anhydrous; c-Met inhibitor 2) is an inhibitor of the N-terminal fragment of Gasdermin D (GSDMD), with an IC50 of 1.04 μM and a Ka of 0.42 μM in mice. SCR-1481B1 effectively blocks GSDMD-NT oligomerization and pore formation, inhibits GSDMD-mediated pyroptosis (Pyroptosis), preserves mitochondrial integrity, and reduces proinflammatory cytokine secretion. SCR-1481B1 also inhibits angiogenesis, exerts GSDMD-independent antitumor effects, and enhances the infiltration of antitumor immune cells. SCR-1481B1 is also an inhibitor targeting to c-MET and VEGFR2, can be used in studies related to melanoma and sepsis .
Cat. No.: HY-172788
CAS No.: 477546-27-3
Target:
Research Areas:
NLRP3-IN-78 (compound 21) is a NLRP3 inhibitor with the inhibition rate of 46.72% in GSDMD-induced pyroptosis at 5 μM. NLRP3-IN-78 binds to the NLRP3 protein and inhibits GSDMD-NT oligomerization. NLRP3-IN-78 also inhibits GSDMD cleavage, and upstream NF-κB signaling, demonstrating its anti-inflammatory activity .
Cat. No.: HY-P83706A
Synonyms: DF 5L; DF5L; DFNA 5L; DFNA5L; FKSG 10; FKSG10; FLJ12150; Gasdermin D; Gasdermin domain coNTaining 1; Gasdermin domain coNTaining protein 1; Gasdermin domain-coNTaining protein 1; Gasdermin-D; GasderminD; GSDMD_HUMAN; GSDMDC 1; GSDMDC1; Gasdermin-D, N-terminal; GSDMD-NT; hGSDMD-NTD; Gasdermin-D, C-terminal; GSDMD-CT; hGSDMD-CTD.
Cat. No.: HY-P11603
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
